Christopher Rovaldi
2022
In 2022, Christopher Rovaldi earned a total compensation of $4.2M as Chief Operating Officer at Keros Therapeutics.
Compensation breakdown
Non-Equity Incentive Plan | $235,000 |
---|---|
Option Awards | $3,538,605 |
Salary | $435,352 |
Other | $38,397 |
Total | $4,247,354 |
Rovaldi received $3.5M in option awards, accounting for 83% of the total pay in 2022.
Rovaldi also received $235K in non-equity incentive plan, $435.4K in salary and $38.4K in other compensation.
Rankings
In 2022, Christopher Rovaldi's compensation ranked 804th out of 5,744 executives tracked by ExecPay. In other words, Rovaldi earned more than 86.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 804 | 86th |
Manufacturing | 365 | 88th |
Chemicals And Allied Products | 123 | 91st |
Drugs | 110 | 92nd |
Pharmaceutical Preparations | 81 | 92nd |
Rovaldi's colleagues
We found two more compensation records of executives who worked with Christopher Rovaldi at Keros Therapeutics in 2022.